Cargando…

Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia

BACKGROUND: Critical limb ischemia (CLI) constitutes the most aggressive form of peripheral arterial occlusive disease, characterized by the blockade of arteries supplying blood to the lower extremities, significantly diminishing oxygen and nutrient supply. CLI patients usually undergo amputation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Beltran-Camacho, Lucia, Jimenez-Palomares, Margarita, Rojas-Torres, Marta, Sanchez-Gomar, Ismael, Rosal-Vela, Antonio, Eslava-Alcon, Sara, Perez-Segura, Mª Carmen, Serrano, Ana, Antequera-González, Borja, Alonso-Piñero, Jose Angel, González-Rovira, Almudena, Extremera-García, Mª Jesús, Rodriguez-Piñero, Manuel, Moreno-Luna, Rafael, Larsen, Martin Røssel, Durán-Ruiz, Mª Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060566/
https://www.ncbi.nlm.nih.gov/pubmed/32143690
http://dx.doi.org/10.1186/s13287-020-01591-0
_version_ 1783504258516123648
author Beltran-Camacho, Lucia
Jimenez-Palomares, Margarita
Rojas-Torres, Marta
Sanchez-Gomar, Ismael
Rosal-Vela, Antonio
Eslava-Alcon, Sara
Perez-Segura, Mª Carmen
Serrano, Ana
Antequera-González, Borja
Alonso-Piñero, Jose Angel
González-Rovira, Almudena
Extremera-García, Mª Jesús
Rodriguez-Piñero, Manuel
Moreno-Luna, Rafael
Larsen, Martin Røssel
Durán-Ruiz, Mª Carmen
author_facet Beltran-Camacho, Lucia
Jimenez-Palomares, Margarita
Rojas-Torres, Marta
Sanchez-Gomar, Ismael
Rosal-Vela, Antonio
Eslava-Alcon, Sara
Perez-Segura, Mª Carmen
Serrano, Ana
Antequera-González, Borja
Alonso-Piñero, Jose Angel
González-Rovira, Almudena
Extremera-García, Mª Jesús
Rodriguez-Piñero, Manuel
Moreno-Luna, Rafael
Larsen, Martin Røssel
Durán-Ruiz, Mª Carmen
author_sort Beltran-Camacho, Lucia
collection PubMed
description BACKGROUND: Critical limb ischemia (CLI) constitutes the most aggressive form of peripheral arterial occlusive disease, characterized by the blockade of arteries supplying blood to the lower extremities, significantly diminishing oxygen and nutrient supply. CLI patients usually undergo amputation of fingers, feet, or extremities, with a high risk of mortality due to associated comorbidities. Circulating angiogenic cells (CACs), also known as early endothelial progenitor cells, constitute promising candidates for cell therapy in CLI due to their assigned vascular regenerative properties. Preclinical and clinical assays with CACs have shown promising results. A better understanding of how these cells participate in vascular regeneration would significantly help to potentiate their role in revascularization. Herein, we analyzed the initial molecular mechanisms triggered by human CACs after being administered to a murine model of CLI, in order to understand how these cells promote angiogenesis within the ischemic tissues. METHODS: Balb-c nude mice (n:24) were distributed in four different groups: healthy controls (C, n:4), shams (SH, n:4), and ischemic mice (after femoral ligation) that received either 50 μl physiological serum (SC, n:8) or 5 × 10(5) human CACs (SE, n:8). Ischemic mice were sacrificed on days 2 and 4 (n:4/group/day), and immunohistochemistry assays and qPCR amplification of Alu-human-specific sequences were carried out for cell detection and vascular density measurements. Additionally, a label-free MS-based quantitative approach was performed to identify protein changes related. RESULTS: Administration of CACs induced in the ischemic tissues an increase in the number of blood vessels as well as the diameter size compared to ischemic, non-treated mice, although the number of CACs decreased within time. The initial protein changes taking place in response to ischemia and more importantly, right after administration of CACs to CLI mice, are shown. CONCLUSIONS: Our results indicate that CACs migrate to the injured area; moreover, they trigger protein changes correlated with cell migration, cell death, angiogenesis, and arteriogenesis in the host. These changes indicate that CACs promote from the beginning an increase in the number of vessels as well as the development of an appropriate vascular network. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7060566
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70605662020-03-12 Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia Beltran-Camacho, Lucia Jimenez-Palomares, Margarita Rojas-Torres, Marta Sanchez-Gomar, Ismael Rosal-Vela, Antonio Eslava-Alcon, Sara Perez-Segura, Mª Carmen Serrano, Ana Antequera-González, Borja Alonso-Piñero, Jose Angel González-Rovira, Almudena Extremera-García, Mª Jesús Rodriguez-Piñero, Manuel Moreno-Luna, Rafael Larsen, Martin Røssel Durán-Ruiz, Mª Carmen Stem Cell Res Ther Research BACKGROUND: Critical limb ischemia (CLI) constitutes the most aggressive form of peripheral arterial occlusive disease, characterized by the blockade of arteries supplying blood to the lower extremities, significantly diminishing oxygen and nutrient supply. CLI patients usually undergo amputation of fingers, feet, or extremities, with a high risk of mortality due to associated comorbidities. Circulating angiogenic cells (CACs), also known as early endothelial progenitor cells, constitute promising candidates for cell therapy in CLI due to their assigned vascular regenerative properties. Preclinical and clinical assays with CACs have shown promising results. A better understanding of how these cells participate in vascular regeneration would significantly help to potentiate their role in revascularization. Herein, we analyzed the initial molecular mechanisms triggered by human CACs after being administered to a murine model of CLI, in order to understand how these cells promote angiogenesis within the ischemic tissues. METHODS: Balb-c nude mice (n:24) were distributed in four different groups: healthy controls (C, n:4), shams (SH, n:4), and ischemic mice (after femoral ligation) that received either 50 μl physiological serum (SC, n:8) or 5 × 10(5) human CACs (SE, n:8). Ischemic mice were sacrificed on days 2 and 4 (n:4/group/day), and immunohistochemistry assays and qPCR amplification of Alu-human-specific sequences were carried out for cell detection and vascular density measurements. Additionally, a label-free MS-based quantitative approach was performed to identify protein changes related. RESULTS: Administration of CACs induced in the ischemic tissues an increase in the number of blood vessels as well as the diameter size compared to ischemic, non-treated mice, although the number of CACs decreased within time. The initial protein changes taking place in response to ischemia and more importantly, right after administration of CACs to CLI mice, are shown. CONCLUSIONS: Our results indicate that CACs migrate to the injured area; moreover, they trigger protein changes correlated with cell migration, cell death, angiogenesis, and arteriogenesis in the host. These changes indicate that CACs promote from the beginning an increase in the number of vessels as well as the development of an appropriate vascular network. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2020-03-06 /pmc/articles/PMC7060566/ /pubmed/32143690 http://dx.doi.org/10.1186/s13287-020-01591-0 Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Beltran-Camacho, Lucia
Jimenez-Palomares, Margarita
Rojas-Torres, Marta
Sanchez-Gomar, Ismael
Rosal-Vela, Antonio
Eslava-Alcon, Sara
Perez-Segura, Mª Carmen
Serrano, Ana
Antequera-González, Borja
Alonso-Piñero, Jose Angel
González-Rovira, Almudena
Extremera-García, Mª Jesús
Rodriguez-Piñero, Manuel
Moreno-Luna, Rafael
Larsen, Martin Røssel
Durán-Ruiz, Mª Carmen
Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
title Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
title_full Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
title_fullStr Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
title_full_unstemmed Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
title_short Identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
title_sort identification of the initial molecular changes in response to circulating angiogenic cells-mediated therapy in critical limb ischemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060566/
https://www.ncbi.nlm.nih.gov/pubmed/32143690
http://dx.doi.org/10.1186/s13287-020-01591-0
work_keys_str_mv AT beltrancamacholucia identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT jimenezpalomaresmargarita identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT rojastorresmarta identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT sanchezgomarismael identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT rosalvelaantonio identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT eslavaalconsara identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT perezseguramacarmen identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT serranoana identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT antequeragonzalezborja identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT alonsopinerojoseangel identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT gonzalezroviraalmudena identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT extremeragarciamajesus identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT rodriguezpineromanuel identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT morenolunarafael identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT larsenmartinrøssel identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia
AT duranruizmacarmen identificationoftheinitialmolecularchangesinresponsetocirculatingangiogeniccellsmediatedtherapyincriticallimbischemia